Skip to main content
Log in

An Institutional Program to Increase Compliance with Clinicaltrials.gov Requirements

  • Clinical Trials: Commentary
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Recent National Institutes of Health policy changes have expanded the number of research studies that must be registered in clinicaltrials.gov beyond the requirements of the Food and Drug Administration Amendments Act of 2007. The International Committee of Medical Journal Editors has also adopted a policy that requires registration of research in a public database. The goal was to increase the transparency of research by reporting the original endpoints of a study, and to discern whether primary endpoints were excluded in subsequent publications. Efforts to increase openness and accountability in clinical trials are likely to strengthen public trust. However, first investigators and study staff must be educated about the requirements, and staff must be prepared to offer support to researchers in navigating the clinicaltrials.gov system. For academic institutions, maintaining compliance requires continuous oversight so that problems can be identified centrally and addressed with investigators. At Wake Forest University Health Sciences, because researchers often did not realize they were out of compliance, we implemented a program to assist them and provide oversight. We introduced standard operating procedures, provided education and assistance to investigators, and engaged leadership about consequences of compliance, resulting in increased budget support for a full-time employee in this role. As a result of these changes, compliance increased from 22% to 92% over 4 months. These approaches may help other institutions become compliant with registration requirements more quickly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Clinical Trials Registration and Results Information Submission Final Rule. Fed Regist. 2016;81:64981–65157.

  2. National Institutes of Health Policy and Compliance [Internet]. https://grants.nih.gov/policy/clinical-trials.htm. Accessed November 5, 2017.

  3. Hudson KL, Lauer MS, Collins FS. Toward a new era of trust and transparency in clinical trials. JAMA. 2016;316:1353–1354.

    Article  Google Scholar 

  4. Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in clinicaltrials.gov—the final rule. N Engl J Med. 2017;375:1998–2004.

    Article  Google Scholar 

  5. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at clinicaltrials.gov. N Engl J Med. 2015;372:1031–1039.

    Article  CAS  Google Scholar 

  6. Guharoy V. Clinicaltrials.gov: is the glass half full? Hosp Pharm. 2014;49:893–895.

    Article  Google Scholar 

  7. Shamliyan TA, Sundarrajan R, Camper D, et al. Sponsorship, conflict of interest, risk of bias, and reporting of participant’s flow and baseline demographic information in studies applicable to the federal law to post the results in clinicaltrials.gov. Contemp Clin Trial Commun. 2017;5:19–25.

    Article  Google Scholar 

  8. Howard B, Scott JT, Blubaugh M, et al. Systematic review: outcome reporting bias is a problem in high impact factor neurology journals. PLoS One. 2017;12:e0180986.

    Article  Google Scholar 

  9. Baudart M, Ravaud P, Baron G, et al. Public availability of results of observational studies evaluating an intervention registered at ClinicalTrials.gov. BMC Med. 2016;14:7.

    Article  Google Scholar 

  10. Canestaro WJ, Hendrix N, Bansal A, et al. Favorable and publicly funded studies are more likely to be published: a systematic review and meta-analysis. J Clin Epidemiol. 2017;92:58–68.

    Article  Google Scholar 

  11. Su EW, Sanger TM. Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov. PeerJ. 2017;5:e3154.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joseph E. Andrews Jr. PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kelly-Pumarol, I., Andrews, J.E. An Institutional Program to Increase Compliance with Clinicaltrials.gov Requirements. Ther Innov Regul Sci 53, 190–192 (2019). https://doi.org/10.1177/2168479018778284

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479018778284

Keywords

Navigation